SCHEMBL3102401

SCHEMBL3102401

CC(Oc1cc2sc(-c3ccc(OC(N)=O)cc3)nc2cc1F)c1c(F)ccc(Cl)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 10/20 0.42
KDR P35968 5/20 0.42
MAPT P10636 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
KMT2A Q03164 2/20 0.39
FGFR2 P21802 3/20 0.39
AXL P30530 3/20 0.39
FLT3 P36888 3/20 0.39
MST1R Q04912 3/20 0.39
AURKA O14965 2/20 0.39
LCK P06239 2/20 0.39
FYN P06241 2/20 0.39
EPHA2 P29317 2/20 0.39
LTK P29376 2/20 0.39
ABL1 P00519 1/20 0.39
YES1 P07947 1/20 0.39
PTK6 Q13882 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3104495 0.96 MET (0.44) METKDRMAPTSMN1; SMN2KDM4E
SCHEMBL3111317 0.93 MET (0.49) METKDRFGFR2AXLFLT3
SCHEMBL3104161 0.90 MET (0.47) METKDRMAPTSMN1; SMN2FGFR2
SCHEMBL3102687 0.90 MAPT (0.40) METKDRMAPTSMN1; SMN2KDM4E
SCHEMBL3106479 0.88 MET (0.49) METKDRMAPTSMN1; SMN2KDM4E
SCHEMBL3110482 0.86 MET (0.48) METKDRFGFR2AXLFLT3
SCHEMBL3102393 0.85 DYRK1A (0.38) METKDRMAPTFGFR2AXL
SCHEMBL3108713 0.83 MET (0.56) METKDRFGFR2AXLFLT3
SCHEMBL3093441 0.83 MET (0.45) METKDRMAPTSMN1; SMN2KDM4E
SCHEMBL3104841 0.83 MET (0.46) METKDRMAPTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 MET 1/4885KDR 41/4885MAPT 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.